Extract
We read with great interest the study by Campredon et al. [1], which was recently published in the European Respiratory Journal. Lumacaftor–ivacaftor combination therapy has achieved clinical benefits in patients with cystic fibrosis homozygous for the Phe508del CFTR mutation. The authors used traditional morphological features on chest computed tomography (CT) to evaluate 1 year of treatment with lumacaftor–ivacaftor and applied pretherapy radiomics morphological features to identify distinct disease phenotypes that were related to treatment response. The results demonstrated that the mean Bhalla total score and subscores significantly reduced after 1 year of treatment, and three clusters could be identified with distinct treatment responses. Notably, patients from cluster C, with younger age and less severe lung structural abnormalities, achieved a better response rate as compared to other clusters. Despite the promising and well-presented findings, we are concerned about several issues described below.
Abstract
Morphological features from chest CT show potential for predicting pulmonary function response during lumacaftor–ivacaftor therapy in cystic fibrosis, but improvements could be made in radiomic workflows and in controlling confounding factors at baseline https://bit.ly/3IJKiDQ
Footnotes
Conflict of interest: B. Zhang has nothing to disclose.
Conflict of interest: S. Zhang has nothing to disclose.
- Received December 3, 2021.
- Accepted December 6, 2021.
- Copyright ©The authors 2022. For reproduction rights and permissions contact permissions{at}ersnet.org